Celcuity (CELC) Competitors $14.64 -0.30 (-2.01%) (As of 11/13/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CELC vs. ENZ, XGN, RNLX, OPGN, ADUS, NHC, FTRE, WGS, TDOC, and VRDNShould you be buying Celcuity stock or one of its competitors? The main competitors of Celcuity include Enzo Biochem (ENZ), Exagen (XGN), Renalytix (RNLX), OpGen (OPGN), Addus HomeCare (ADUS), National HealthCare (NHC), Fortrea (FTRE), GeneDx (WGS), Teladoc Health (TDOC), and Viridian Therapeutics (VRDN). These companies are all part of the "healthcare" industry. Celcuity vs. Enzo Biochem Exagen Renalytix OpGen Addus HomeCare National HealthCare Fortrea GeneDx Teladoc Health Viridian Therapeutics Celcuity (NASDAQ:CELC) and Enzo Biochem (NYSE:ENZ) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations, valuation and community ranking. Do analysts recommend CELC or ENZ? Celcuity presently has a consensus target price of $29.17, suggesting a potential upside of 99.23%. Given Celcuity's stronger consensus rating and higher probable upside, analysts clearly believe Celcuity is more favorable than Enzo Biochem.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celcuity 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Enzo Biochem 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders hold more shares of CELC or ENZ? 63.3% of Celcuity shares are held by institutional investors. Comparatively, 36.9% of Enzo Biochem shares are held by institutional investors. 15.8% of Celcuity shares are held by insiders. Comparatively, 15.5% of Enzo Biochem shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is CELC or ENZ more profitable? Celcuity has a net margin of 0.00% compared to Enzo Biochem's net margin of -81.73%. Enzo Biochem's return on equity of -11.84% beat Celcuity's return on equity.Company Net Margins Return on Equity Return on Assets CelcuityN/A -60.83% -40.57% Enzo Biochem -81.73%-11.84%-8.31% Does the media refer more to CELC or ENZ? In the previous week, Celcuity had 3 more articles in the media than Enzo Biochem. MarketBeat recorded 5 mentions for Celcuity and 2 mentions for Enzo Biochem. Celcuity's average media sentiment score of 0.09 beat Enzo Biochem's score of 0.00 indicating that Celcuity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celcuity 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Enzo Biochem 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger valuation and earnings, CELC or ENZ? Enzo Biochem has higher revenue and earnings than Celcuity. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCelcuityN/AN/A-$63.78M-$2.74-5.34Enzo Biochem$31.91M1.87-$26.08MN/AN/A Does the MarketBeat Community favor CELC or ENZ? Celcuity received 123 more outperform votes than Enzo Biochem when rated by MarketBeat users. Likewise, 67.40% of users gave Celcuity an outperform vote while only 55.50% of users gave Enzo Biochem an outperform vote. CompanyUnderperformOutperformCelcuityOutperform Votes33567.40% Underperform Votes16232.60% Enzo BiochemOutperform Votes21255.50% Underperform Votes17044.50% Which has more risk & volatility, CELC or ENZ? Celcuity has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500. Comparatively, Enzo Biochem has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500. SummaryCelcuity beats Enzo Biochem on 12 of the 16 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide Get Celcuity News Delivered to You Automatically Sign up to receive the latest news and ratings for CELC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CELC vs. The Competition Export to ExcelMetricCelcuityMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$542.12M$2.94B$5.16B$8.94BDividend YieldN/A1.67%5.04%4.03%P/E Ratio-5.3413.3797.1815.21Price / SalesN/A196.121,298.2292.29Price / CashN/A381.6139.4036.42Price / Book2.673.336.425.98Net Income-$63.78M-$32.88M$115.02M$225.08M7 Day Performance-9.91%-0.65%-0.77%0.37%1 Month Performance-3.43%-1.00%4.85%5.73%1 Year Performance34.44%38.15%41.37%31.75% Celcuity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CELCCelcuity2.1986 of 5 stars$14.64-2.0%$29.17+99.2%+38.7%$542.12MN/A-5.3440Upcoming EarningsNews CoverageENZEnzo Biochem0.0881 of 5 stars$1.15flatN/A-5.7%$59.56M$31.91M0.00520High Trading VolumeXGNExagen4.482 of 5 stars$2.97+4.2%N/A+92.4%$51.64M$56.66M-3.06220Earnings ReportAnalyst ForecastShort Interest ↑News CoverageGap UpRNLXRenalytix1.4561 of 5 stars$0.21+5.7%N/A-77.2%$17.18M$2.29M-0.53100Gap UpOPGNOpGenN/A$1.60-5.9%N/A-72.5%$13.38M$3.42M0.00100Gap UpADUSAddus HomeCare4.7004 of 5 stars$127.95+0.3%N/A+53.2%$2.31B$1.06B29.2834,846NHCNational HealthCareN/A$135.76+1.0%N/AN/A$2.09B$1.18B17.0113,123Dividend AnnouncementFTREFortrea2.4112 of 5 stars$22.75-3.2%N/A-22.2%$2.04B$3.11B-6.6518,000Earnings ReportAnalyst ForecastGap DownWGSGeneDx1.4547 of 5 stars$73.39-5.7%N/A+5,956.7%$2.02B$267.23M-23.601,200Positive NewsTDOCTeladoc Health3.1611 of 5 stars$9.81+6.2%N/A-39.2%$1.69B$2.59B-1.705,600Gap UpVRDNViridian Therapeutics2.4532 of 5 stars$25.71+2.0%N/A+63.0%$1.64B$288,000.00-6.0550Analyst ForecastNews Coverage Related Companies and Tools Related Companies Enzo Biochem Competitors Exagen Competitors Renalytix Competitors OpGen Competitors Addus HomeCare Competitors National HealthCare Competitors Fortrea Competitors GeneDx Competitors Teladoc Health Competitors Viridian Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CELC) was last updated on 11/13/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celcuity Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celcuity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
